Tezepelumab COPD Exacerbation Study
Public ClinicalTrials.gov record NCT04039113. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE)
Study identification
- NCT ID
- NCT04039113
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 337 participants
Conditions and interventions
Conditions
Interventions
- Placebo Other
- Tezepelumab Biological
Other · Biological
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 29, 2019
- Primary completion
- Nov 9, 2023
- Completion
- Jan 30, 2024
- Last update posted
- Feb 17, 2025
2019 – 2024
United States locations
- U.S. sites
- 27
- U.S. states
- 16
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Dothan | Alabama | 36305 | — |
| Research Site | Huntington Beach | California | 92647 | — |
| Research Site | Newport Beach | California | 92663 | — |
| Research Site | Upland | California | 91786 | — |
| Research Site | Westminster | California | 92683 | — |
| Research Site | New Haven | Connecticut | 06510 | — |
| Research Site | Brandon | Florida | 33511 | — |
| Research Site | Orlando | Florida | 32819 | — |
| Research Site | Panama City | Florida | 32405 | — |
| Research Site | Tampa | Florida | 33607 | — |
| Research Site | Winter Park | Florida | 32789-4681 | — |
| Research Site | Buckley | Michigan | 49620 | — |
| Research Site | Albuquerque | New Mexico | 87108 | — |
| Research Site | Charlotte | North Carolina | 28277 | — |
| Research Site | Mooresville | North Carolina | 28117 | — |
| Research Site | New Bern | North Carolina | 28562 | — |
| Research Site | Columbus | Ohio | 43215 | — |
| Research Site | Edmond | Oklahoma | 73034 | — |
| Research Site | Medford | Oregon | 97504 | — |
| Research Site | Philadelphia | Pennsylvania | 19140 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | Mt. Pleasant | South Carolina | 29464 | — |
| Research Site | Rock Hill | South Carolina | 29732 | — |
| Research Site | Rapid City | South Dakota | 57702 | — |
| Research Site | McKinney | Texas | 75069 | — |
| Research Site | Abingdon | Virginia | 24210 | — |
| Research Site | Everett | Washington | 98208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04039113, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2025 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04039113 live on ClinicalTrials.gov.